Genomic Health's Oncotype DX Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Genomic Health, Inc. today announced positive results from the landmark QUASAR validation study, which demonstrated that the Oncotype DX (R) colon cancer test can independently predict individual recurrence risk in stage II colon cancer patients following surgery.



You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.